Before and After Photos

The photos below are actual patient images from Enstilar® clinical trials. They show before treatment and after at Week 1 and Week 4 of therapy.

Clinical Trial Images

Actual patient images

Arm

Leg

Elbow

Knee

A randomized clinical trial with 426 patients investigated the effectiveness of Enstilar® spray foam or the vehicle alone for the treatment of psoriasis vulgaris on the trunk and/or limbs. Efficacy was assessed using a 5-point IGA at Week 4, with treatment success defined as the percentage of patients who achieved at least a 2-step improvement to reach "Clear" or "Almost Clear" disease severity. Patients with "Mild" disease were required to be "Clear" to be considered a treatment success.

Before and After Photos

The photos below are actual patient images from Enstilar® clinical trials. They show before treatment and after at Week 1 and Week 4 of therapy.

Clinical Trial Images

Actual patient images

Baseline

Arm
Leg
Elbow
Knee

Week 1

Arm
Leg
Elbow
Knee

Week 4

Arm
Leg
Elbow
Knee

A randomized clinical trial with 426 patients investigated the effectiveness of Enstilar® spray foam or the vehicle alone for the treatment of psoriasis vulgaris on the trunk and/or limbs. Efficacy was assessed using a 5-point IGA at Week 4, with treatment success defined as the percentage of patients who achieved at least a 2-step improvement to reach "Clear" or "Almost Clear" disease severity. Patients with "Mild" disease were required to be "Clear" to be considered a treatment success.

Before and After Photos

The photos below are actual patient images from Enstilar® clinical trials. They show before treatment and after at Week 1 and Week 4 of therapy.

Clinical Trial Images

Actual patient images

Baseline

Arm
Leg
Elbow
Knee

Week 1

Arm
Leg
Elbow
Knee

Week 4

Arm
Leg
Elbow
Knee

A randomized clinical trial with 426 patients investigated the effectiveness of Enstilar® spray foam or the vehicle alone for the treatment of psoriasis vulgaris on the trunk and/or limbs. Efficacy was assessed using a 5-point IGA at Week 4, with treatment success defined as the percentage of patients who achieved at least a 2-step improvement to reach "Clear" or "Almost Clear" disease severity. Patients with "Mild" disease were required to be "Clear" to be considered a treatment success.

Important Safety Information

Enstilar® Foam is for use on skin only (topical). Do not get Enstilar® Foam in your mouth, eyes, or vagina. Avoid using Enstilar® Foam on your face, groin, or under your arms, or if you have thinning of your skin (atrophy) at the treatment site.

Enstilar® Foam is easily set on fire; avoid heat, flame, or smoking during and right after applying this medication.

Enstilar® Foam may cause serious side effects including too much calcium in your blood or urine and/or adrenal gland problems. You may experience skin problems including allergic reactions. If you get Enstilar® Foam in the mouth or in the eyes, wash the area with water right away. Wash your hands after using Enstilar® Foam unless you are using the medicine to treat your hands. Do not bandage or cover the treated skin area, unless instructed by your doctor.

The most common side effects include irritation, itching, inflammation, changes in skin color, rash, and worsening of your psoriasis. Tell your doctor if you have a calcium metabolism disorder, have thinning-skin (atrophy) at the site to be treated, are getting light therapy (phototherapy treatments) for your psoriasis, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Do not use Enstilar® Foam on your breast if you breastfeed. Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins and herbal supplements. Be sure to tell your doctor if you use other corticosteroid medicines and/or other medicines for your psoriasis. Avoid spending a long time in the sunlight and avoid tanning booths and sun lamps.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication and Usage

Enstilar® (calcipotriene and betamethasone dipropionate) Foam is a prescription medicine used on the skin to treat plaque psoriasis in adult patients 18 years of age and older.

Apply Enstilar® Foam to the affected areas of your skin 1 time a day for up to 4 weeks. You should stop treatment when your plaque psoriasis is under control, unless your doctor gives you other instructions. Do not use more than 60 grams of Enstilar® Foam every 4 days. Use Enstilar® Foam exactly as your doctor tells you to use it.

Please click here for Enstilar® Full Prescribing Information.



*Valid for up to 12 prescription fills per calendar year — up to a maximum of $6,000 per year. Patients are not eligible if they are enrolled in or eligible for any state or federally funded health care program (eg, Medicare, Medicaid). Additional restrictions and limitations apply. Click here for eligibility criteria.

LEO, the LEO Lion Design, and Enstilar are registered trademarks of LEO Pharma A/S.
© 2018 LEO Pharma Inc. All rights reserved. August 2018 MAT-18460
LEO, the LEO Lion Design, Leo Pharma and Enstilar are registered trademarks of LEO Pharma A/S.
© 2018 LEO Pharma Inc. All rights reserved. August 2018 MAT-18460
LEO, the LEO Lion Design, Leo Pharma and Enstilar are registered trademarks of LEO Pharma A/S.
© 2018 LEO Pharma Inc. All rights reserved. August 2018 MAT-18460